Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: J Psychiatr Res. 2016 Sep 30;84:90–97. doi: 10.1016/j.jpsychires.2016.09.029

Figure 1. Modeled GAD-7 symptom improvement during treatment as a function of baseline efficacy expectancy.

Figure 1

Individuals with more efficacy expectancy experienced more GAD-7 symptomatic change over the course of the trial (p = 0.008). Modeled symptom trajectories displayed for different levels of efficacy expectancy with the same baseline symptom severity.